Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03900949
Title Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute

acute myeloid leukemia




Cytarabine + Gemtuzumab ozogamicin

Cytarabine + Daunorubicin + Gemtuzumab ozogamicin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST